Site icon Impactiviti

Impactiviti Daily 033010



Patenting genes called into question. Frankly, this is a legal/medical/sociological discussion that needs to happen.

Cephalon‘s jet lag indication on Nuvigil may be stuck on the runway for a while.

When companies – and agencies – can’t count. An expensively amusing tale.

The Top 20 Drugmakers, listed.

Another experimental cancer drug hits the wall. That’s two in two days. Bummer.


POA/Sales Meeting Training – If you are responsible for training during periodic “live” meetings, let’s discuss the programs you’re looking for. The Impactiviti partner network can undoubtedly help.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

The latest Impactiviti Connection e-newsletter is up! You can subscribe here.


Huw Tippett, head of global sales for Novartis, explains his firm’s new focus on creating customer value and unlocking value from key accounts – Why Pharma Needs a New Commercial Model.


What’s really inside your computer? Intel….or her?
EVENT – Coming up May 11 – BDI’s Social Communications and Healthcare Case Studies and Roundtables. I’ll be attending/facilitating. Use discount code IMPACT for $155 reg. rate:


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)


Exit mobile version